Major Shareholding Notification • Sep 28, 2018
Major Shareholding Notification
Open in ViewerOpens in native device viewer
Regulated information
Brussels, Belgium, 28 September 2018, 6.00 pm (CET) – ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 24 September, 2018, the result of which is - following a capital increase completed on September 6th – that SA S.R.I.B. and SA Brustart have now jointly 4,92% of the Company's voting rights, and has thus decreased their stake below the 5% threshold.
The statement dated 24 September, 2018 notably includes the following information:
Passive crossing of a threshold
• Notification by
A parent undertaking or a controlling person
• Person subject to the notification requirement
S.R.I.B. SA – Rue Stassart 32, 1050 Bruxelles Brustart SA – Rue Stassart 32, 1050 Bruxelles
• Date of the transaction
September 6th , 2018
• Threshold crossed (%)
Downward crossing of the 5% threshold
• Denominator
A total of 17,506,777 voting rights
• This notification is available on ASIT biotech's website, in the Documentation / Regulated information section:
https://www.asitbiotech.com/investors/documentation
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at www.asitbiotech.com.
Company Thierry Legon, CEO ASIT biotech Tel.: +32 2 264 03 90
Media and Investor Relations - France NewCap Dusan Oresansky / Pierre Laurent Tel.: +33 1 44 71 94 92 [email protected]
Tel.: +32 2 290 90 93 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.